Neurocrine Biosciences
NBIX
150.57
-6.02
-3.84%
Neurocrine Biosciences
US · NBIX
#1162 by market cap
Listed 1970
150.57
-6.02
-3.84%
Periodic snapshot; not a real-time feed.
· 2026-11-20 20:02
Quant vs Street three independent views, side by side
StockVane factor grade
A+
Momentum strategy signal
Hold
Analyst consensus
Buy
Mostly aligned, one view stands apart.
Not investment advice. The factor grade ranks this stock on fundamentals against StockVane's covered universe; the momentum strategy signal is a rules-based backtest, not a recommendation; analyst consensus reflects sell-side coverage. The three use different methods and can reasonably disagree.
✦ Quant Analyst Revision Trend how this is computed
Mixed
1
■ Upgrades■ Downgrades
- 0 upgrades vs 1 downgrade among tracked analyst rating changes.
- Most recent: Morgan Stanley moved from Buy to Hold on 2026-01-08.
Analyst consensus 19 analysts
Buy
Avg price target 207.35 +37.7%
Price target rangecurrent 150.57
Low150.00
Avg207.35
High253.00
Buy 84%
Hold 16%
Sell 0%
Recent ratings (25)
| Date | Firm | Analyst | Rating | Target |
|---|---|---|---|---|
| 2026-11-13 | Morgan Stanley | -- | Hold | 191.00 |
| 2026-11-03 | TD Cowen | -- | Buy | 220.00 |
| 2026-11-03 | CCORF | -- | Buy | 220.00 |
| 2026-11-03 | Wells Fargo | -- | Buy | 200.00 |
| 2026-11-03 | Bernstein | -- | Buy | 218.00 |
| 2026-11-03 | Piper Sandler | -- | Buy | 215.00 |
| 2026-11-03 | BofA Securities | -- | Buy | -- |
| 2026-11-03 | Wedbush | -- | Buy | 186.00 |
| 2026-11-03 | Morgan Stanley | -- | Hold | 185.00 |
| 2026-11-03 | Deutsche Bank | -- | Hold | 175.00 |
| 2026-11-03 | Guggenheim | -- | Buy | 224.00 |
| 2026-11-03 | Oppenheimer | -- | Buy | 230.00 |
| 2026-11-02 | Cantor Fitzgerald | -- | Buy | 215.00 |
| 2026-11-02 | Morgan Stanley | -- | Hold | 183.00 |
| 2026-11-02 | BMO Capital | -- | Hold | 150.00 |
| 2026-11-02 | RBC Capital | -- | Buy | 190.00 |
| 2026-11-02 | J.P. Morgan | -- | Buy | -- |
| 2026-10-16 | Needham | -- | Buy | 204.00 |
| 2026-10-13 | Wells Fargo | -- | Buy | 200.00 |
| 2026-10-13 | RBC Capital | -- | Buy | 187.00 |
| 2026-10-12 | BMO Capital | -- | Hold | 150.00 |
| 2026-10-09 | Piper Sandler | -- | Buy | 210.00 |
| 2026-10-09 | BofA Securities | -- | Buy | 214.00 |
| 2026-10-08 | RBC Capital | -- | Buy | 187.00 |
| 2026-10-05 | Guggenheim | -- | Buy | 207.00 |
Price target trend monthly average, last 3 years
Recent rating changes
| Date | Firm | Change | Target |
|---|---|---|---|
| 2026-01-08 | Morgan Stanley | Buy → Hold | 175.00 |
Earnings history price reaction on the day
| Period | Report date | Session | Options expected | Actual move |
|---|---|---|---|---|
| 2026/Q3 | 2026-11-02 | After close | ±9.60% | +13.42% (beat) |
| 2026/Q2 | 2026-07-30 | After close | ±8.09% | -10.08% (beat) |
| 2026/Q1 | 2026-05-05 | After close | ±7.44% | +8.86% (beat) |
| 2025/Q4 | 2026-02-11 | After close | ±6.70% | -10.43% (beat) |
| 2025/Q3 | 2025-10-28 | After close | ±8.87% | -6.35% (in line) |
| 2025/Q2 | 2025-07-30 | After close | ±9.19% | -6.24% (in line) |
| 2025/Q1 | 2025-05-05 | After close | ±12.38% | +8.36% (in line) |
| 2024/Q4 | 2025-02-06 | After close | ±7.76% | -18.53% (beat) |
| 2024/Q3 | 2024-10-30 | -- | ±8.10% | +7.01% (in line) |
| 2024/Q2 | 2024-08-01 | -- | ±16.25% | +8.18% (in line) |
| 2024/Q1 | 2024-05-01 | -- | ±7.33% | +3.99% (in line) |
| 2023/Q4 | 2024-02-07 | -- | ±7.12% | -4.67% (in line) |
"Options expected" is the pre-earnings options market's implied move (a straddle-style estimate), shown next to what actually happened.
Quote time 2026-11-20 20:02:19 · For reference only, not investment advice and not tailored to your situation.
Neurocrine Biosciences discussion 0 comments